Biomaterial Database

[Treatment and challenges of bulevirtide in chronic hepatitis D]. 2022

X B Lu, and X Z Wang

Infectious Disease Center, the First Affiliated Hospital of Xinjiang Medical University, Urumqi 830000, China.

In July of 2020, bulevirtide was conditionally approved for the treatment of adults with compensated chronic hepatitis D. Some clinical studies have evaluated the safety and efficacy of bulevirtide as a treatment option for chronic hepatitis D in recent years. Herein are presented a brief review and an outline.

UI	MeSH Term	Description	Entries
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328	Adult	A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available.	Adults
D000998	Antiviral Agents	Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly.	Antiviral,Antiviral Agent,Antiviral Drug,Antivirals,Antiviral Drugs,Agent, Antiviral,Agents, Antiviral,Drug, Antiviral,Drugs, Antiviral
D055666	Lipopeptides	Compounds consisting of a short peptide chain conjugated with an acyl chain.	Lipopeptide,Anionic Lipopeptide,Anionic Lipopeptides,Cationic Lipopeptide,Cationic Lipopeptides,Lipopeptide, Anionic,Lipopeptide, Cationic,Lipopeptides, Anionic,Lipopeptides, Cationic
D019701	Hepatitis D, Chronic	INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS in conjunction with HEPATITIS B VIRUS and lasting six months or more.	Chronic Delta Hepatitis,Chronic Hepatitis D,Delta Hepatitis, Chronic,Chronic Delta Hepatitides,Delta Hepatitides, Chronic,Hepatitides, Chronic Delta,Hepatitis, Chronic Delta